Navigation Links
Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs
Date:7/18/2014

se, being developed in collaboration with BRNI, is scheduled to commence in July 2014.  

Please visit www.neurotropebioscience.com for further information.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements.  Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of commercially viable pharmaceuticals, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above.  Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over.  Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.  Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company's inability
'/>"/>

SOURCE Neurotrope, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
2. Neurotrope, Inc., Announces New Trading Symbol
3. Blanchette Rockefeller Neurosciences Institute Partners with Neurotrope BioScience to Advance New Alzheimers Disease Discoveries
4. Dr. Jim Vaught, Ph.D., Former Chief of BBRB, Joins Provia Laboratories as Advisory Board Member
5. PharmaBoardroom Releases New Poland Pharmaceutical Report
6. Dr. Iffath Abbasi Hoskins Joins Americords Advisory Board
7. Reagan-Udall Foundation Announces New Board Chairman
8. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
9. Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board
10. Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors
11. Burzynski Clinic Announces the Response to the Allegations and Complaint by the Texas Medical Board Against Dr. Burzynski
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015  AsureQuality and Ubiquitome have agreed ... applications in food and primary production sectors. The ... PCR device, the Freedom4. AsureQuality provides ... the supermarket shelf for producers, processors and Competent ... animal disease control and pest management and surveillance ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... The third ... of combination products , in particular, drug/device combinations. The current system received a ... the Initiative for Patient Centered Innovation (iPCI) of Fairleigh Dickinson University’s ( ...
(Date:7/29/2015)... ... July 29, 2015 , ... CSSi LifeSciences™ formalized ... specializing in Clinical Trial Management. CSSi LifeSciences is specialized in strategic, marketing, and ... PRC Clinical is focused on Clinical Trial Management, Clinical Site Monitoring, and Clinical ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3
... LOUIS, June 10 KV Pharmaceutical Company,(NYSE: ... that,develops, manufactures, acquires and markets technology-differentiated,branded products ... has become aware of litigation filed by ... challenging the patent rights,associated with PrimaCare ONE(R), ...
... pipeline of biologics ... disease and cancer, CAMBRIDGE, Mass., June 10 Merrimack ... of,novel treatments for autoimmune disease and cancer, today announced that ... financing., Existing and new investors participated in the financing ...
... - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced ... Phase 1/2 clinical trial for patients with,metastatic ... concurrent,intravenous (IV) and intraperitoneal (IP) administration of ... The National,Cancer Institute (NCI), part of the ...
Cached Biology Technology:KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business 2KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business 3Merrimack Pharmaceuticals Raises $60 Million in Private Financing 2Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R) 2Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R) 3
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... it has filed provisional patent 62/198989 for ... invention highlights a method to advance crypto-currencies such as ... introducing a common, uniform way to manage all payments.  ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... C (4.3 F) above pre-industrial levels even under extremely ... efforts to clean up particulate pollution continue to be ... of researchers at Scripps Institution of Oceanography at UC ... what the world,s leading climate change authority recently set ...
... By coupling a kicked-up version of microscopy with miniscule particles ... so deep into living tissue that they can see molecules ... the researchers believe that their new approach can have a ... a tumor as it is removed from the body to ...
... Cambridge, UK Any way you slice it, the ... , The planarian, a flatworm normally living in freshwater, ... a single planarian cut into 200 pieces can generate 200 ... not merely a fascinating master of regeneration, but can help ...
Cached Biology News:Warming world in range of dangerous consequences 2Warming world in range of dangerous consequences 3New technique sees into tissue at greater depth, resolution 2New technique sees into tissue at greater depth, resolution 3
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
Biology Products: